Blog Big Molecule Watch October 31, 2017

Pfizer and Celltrion Healthcare Reveal New Data For infliximab biosimilar Inflectra®

Last year we reported the FDA approval and then U.S. launch of Inflectra®, a biosimilar of Remicade® (infliximab). This week, Pfizer and Celltrion Healthcare have reported that the results of a Phase 3 study of Inflectra demonstrated that “switching patients with Crohn’s disease (CD) to Inflectra from Remicade® (infliximab) led to comparable efficacy, safety and tolerability to treatment with Remicade® over a 24 week period.” The results also demonstrated that Inflectra® was well-tolerated, with a similar safety profile to Remicade®.

Full results were presented at the 25th United European Gastroenterology Week conference that took place over this past weekend in Barcelona.

The post Pfizer and Celltrion Healthcare Reveal New Data For infliximab biosimilar Inflectra® appeared first on Goodwin Procter BioSimilars Blog.